Innovent Biologics IncInnovent Biologics Inc - ESG Rating & Company Profile powered by AI

Industry Group:Pharmaceuticals

Full Sustainability assessment of Innovent Biologics Inc can be reached by logging in. The article includes a Q&A table for Innovent Biologics Inc. If you work at Innovent Biologics Inc and you would like to use your Sustainability aseessment, please contact us.

Innovent Biologics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.1; made up of an environmental score of 3.0, social score of 1.0 and governance score of 2.3.

SDG Transparency Score for Innovent Biologics Inc 

2.1

Low Impact
0 - 3
Medium
4 - 6
High
7 - 10
Last Score Update: 2024-05-01
What drives the score for Innovent Biologics Inc 
3.0

Environmental

1.0

Social

2.3

Governance

Detailed ESG Breakdown
SEVVA Platform offers unique drill down to the underlying sources powering the ratings. Break down your ESG analysis by 17 UN SDGs and 8 additional governance factors.

Peer Group Comparison

RankCompanySDG Transparency Score Performance
1Caladrius Biosciences Inc
8.0
High
1Can Fite Biopharma Ltd
8.0
High
.........
1551Voyager Life PLC
2.2
Medium
1551Source Natural Foods and Herbal Supplements Ltd
2.2
Medium
1571Innovent Biologics Inc
2.1
Medium
1571Cerevel Therapeutics Holdings Inc
2.1
Medium
1571Charlotte's Web Holdings Inc
2.1
Medium
.........
1970Zyden Gentec Ltd
0.0
Low
1970iNtRON Biotechnology Inc
0.0
Low
.........
View the full peer group of 3273 companies on the SEVVA platformSign up for free
Peer Companies Benchmark
SEVVA Platform benchmarks each company against a peer group. View the full score distribution for peers by logging into SEVVA

Frequently Asked Questions

Does Innovent Biologics Inc have an accelerator or VC vehicle to help deliver innovation?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose current and historical energy intensity?

LockedSign up for free to unlock

Does Innovent Biologics Inc report the average age of the workforce?

LockedSign up for free to unlock

Does Innovent Biologics Inc reference operational or capital allocation in relation to climate change?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose its ethnicity pay gap?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose cybersecurity risks?

LockedSign up for free to unlock

Does Innovent Biologics Inc offer flexible work?

LockedSign up for free to unlock

Does Innovent Biologics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose the number of employees in R&D functions?

LockedSign up for free to unlock

Does Innovent Biologics Inc conduct supply chain audits?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')

LockedSign up for free to unlock

Does Innovent Biologics Inc conduct 360 degree staff reviews?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose the individual responsible for D&I?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose current and historical air emissions?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')

LockedSign up for free to unlock

Is executive remuneration linked to climate performance?

LockedSign up for free to unlock

Does the Board describe its role in the oversight of climate-related risks and opportunities?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose current and / or historical scope 2 emissions?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose water use targets?

LockedSign up for free to unlock

Does Innovent Biologics Inc have careers partnerships with academic institutions?

LockedSign up for free to unlock

Did Innovent Biologics Inc have a product recall in the last two years?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose incidents of discrimination?

LockedSign up for free to unlock

Does Innovent Biologics Inc allow for Work Councils/Collective Agreements to be formed?

LockedSign up for free to unlock

Has Innovent Biologics Inc issued a profit warning in the past 24 months?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose parental leave metrics?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose climate scenario or pathway analysis?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose current and / or historical scope 1 emissions?

LockedSign up for free to unlock

Are Operating Expesnses linked to emissions reduction?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose the pay ratio of women to men?

LockedSign up for free to unlock

Does Innovent Biologics Inc support suppliers with sustainability related research and development?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?

LockedSign up for free to unlock

Does Innovent Biologics Inc reflect climate-related risks in its financial statements?

LockedSign up for free to unlock

Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')

LockedSign up for free to unlock

Is Innovent Biologics Inc involved in embryonic stem cell research?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose GHG and Air Emissions intensity?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose its waste policy?

LockedSign up for free to unlock

Does Innovent Biologics Inc report according to TCFD requirements?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose energy use targets?

LockedSign up for free to unlock

Does Innovent Biologics Inc disclose its Renewable Energy targets?

Only SubscribersSubscription required

Are emissions metrics verified by STBi?

Only SubscribersSubscription required

Does Innovent Biologics Inc have a policy relating to cyber security?

LockedSign up for free to unlock

Have a different question?

Potential Risks for Innovent Biologics Inc
These potential risks are based on the size, segment and geographies of the company.

Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.

Sorry!

Failed to process!